BridgeBio Pharma (BBIO) Projected to Post Earnings on Thursday

BridgeBio Pharma (NASDAQ:BBIO) will likely be posting its quarterly earnings results on Thursday, February 20th. Analysts expect BridgeBio Pharma to post earnings of ($0.82) per share and revenue of $39.44 million for the quarter.

BridgeBio Pharma Stock Up 2.7 %

BridgeBio Pharma stock opened at $31.95 on Thursday. BridgeBio Pharma has a 12-month low of $21.62 and a 12-month high of $41.04. The stock has a market cap of $6.04 billion, a price-to-earnings ratio of -13.26 and a beta of 1.07. The business’s 50-day simple moving average is $30.83 and its 200 day simple moving average is $27.46.

Wall Street Analyst Weigh In

Several research firms recently issued reports on BBIO. HC Wainwright reaffirmed a “buy” rating and issued a $49.00 price objective on shares of BridgeBio Pharma in a report on Monday, December 16th. Bank of America upped their price target on BridgeBio Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, November 25th. Evercore ISI increased their price target on BridgeBio Pharma from $45.00 to $50.00 and gave the stock an “outperform” rating in a report on Monday, December 23rd. Scotiabank lifted their price target on BridgeBio Pharma from $48.00 to $49.00 and gave the stock a “sector outperform” rating in a report on Wednesday. Finally, Leerink Partners reduced their price target on BridgeBio Pharma from $47.00 to $46.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. One equities research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $49.08.

Insider Activity at BridgeBio Pharma

In other news, CFO Brian C. Stephenson sold 4,156 shares of the firm’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $22.41, for a total value of $93,135.96. Following the sale, the chief financial officer now directly owns 93,758 shares in the company, valued at approximately $2,101,116.78. This trade represents a 4.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Neil Kumar sold 27,389 shares of BridgeBio Pharma stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $22.41, for a total transaction of $613,787.49. Following the sale, the chief executive officer now owns 4,897,443 shares in the company, valued at $109,751,697.63. This represents a 0.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 3,492,093 shares of company stock valued at $122,029,004. Corporate insiders own 24.66% of the company’s stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.